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Lotti Tajouri2, Daniel Peterson6, Sandra B Ramos2 and Sonya M Marshall-Gradisnik1,2,3Abstract
Background: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is an etiologically unexplained
disorder characterised by irregularities in various aspects of the immunological function. Presently, it is unknown
whether these immunological changes remain consistent over time. This study investigates Natural Killer (NK) cell
cytotoxic activity, NK cell subsets (CD56brightCD16- and CD56dimCD16+) and cytokines, over the course of a12 month
period in patients with CFS/ME.
Methods: The participants in the study comprised 65 (47.2 ± 11.5 years) CFS/ME participants and 21 (45.2
±9.3 years) non-fatigued controls. Flow cytometry protocols were used to assess NK subsets and NK cytotoxic
activity at various time points that included baseline (T1), 6 (T2) and 12 months (T3). Cytokine secretions were
measured following mitogenic stimulation of peripheral blood mononuclear cells.
Results: NK cytotoxic activity was significantly decreased in the CFS/ME patients at T1, T2 and T3 compared to the
non-fatigued group. Additionally, in comparison to the non-fatigued controls, the CFS/ME group had significantly
lower numbers of CD56brightCD16- NK cells at both T1 and T2. Interestingly, following mitogenic stimulation,
cytokine secretion revealed significant increases in IL-10, IFN-γ and TNF-α at T1 in the CFS/ME group. A significant
decrease was observed at T2 in the CFS/ME group for IL-10 and IL-17A while at T3, IL-2 was increased in the
CFS/ME group in comparison to the non-fatigued controls. Overall cytotoxic activity was significantly decreased at
T3 compared to T1 and T2. CD56brightCD16- NK cells were much lower at T2 compared to T1 and T3. IL-10 and IL-17A
secretion was elevated at T2 in comparison to T1 and T3.
Conclusion: These results confirm decreases in immune function in CFS/ME patients, suggesting an increased
susceptibility to viral and other infections. Furthermore, NK cytotoxic activity may be a suitable biomarker for
diagnosing CFS/ME as it was consistently decreased during the course of the 12 months study.
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Table 1 Baseline clinical characteristics of chronic fatigue
syndrome patients (cases) and non-fatigued controls
Cases (n=65) Controls (n=21)
Age, mean in years (SD) 47.2 (11.5) 45.2 (9.3)
Female (%) 75.4 66.7
BMI kg/m2 (SD) 24.4 (4.9) 25.3 (5.5)
Smoked in the past 2 years (%) 4.7 4.8
Symptom (%)
Weakness >24 hours after exercise 93.8 9.5
Unrefreshing sleep 93.8 19.0
Impaired concentration 90.8 4.8
Muscle pain 81.5 14.3
Joint pain 70.8 9.5
Headaches 67.7 9.5
Lymph glands 43.1 0
Sore throat 46.2 8.0
Diagnosed with depression or anxiety 64.6 19.0
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Immune responses to infection and inflammation are
important aspects of physiological homeostasis. This
involves constant co-ordinated responses from and be-
tween the innate and adaptive immune systems [1,2].
Cells of the innate immune system in particular Natural
Killer (NK) cells are important mediators of targeted cell
killing of tumor, transformed and virus infected cells [3].
NK cells are recruited by interferons and chemoattrac-
tive chemokines including CCL22, CX3CL1 and CXCL8
[4-7]. At sites of infection, stochastic expression of NK
receptors with the release of granzymes and perforin via
mitogenic pathways ensures efficient elimination of un-
wanted cells [8-11].
As a disease with unknown pathomechanism and
lacking specific diagnostic markers, Chronic Fatigue
Syndrome/Myalgic Encephalomyelitis (CFS/ME) has
been associated with diminished immune function [12].
CFS/ME is characterised by severe fatigue with apparent
flu-like symptoms that either fluctuate or deteriorate
and persist for many months to years [13,14]. To date
cytokines, lymphocyte subsets and cytotoxic activity,
have been examined in patients with CFS/ME using
serum, plasma or blood samples. The findings from
these investigations demonstrate equivocal quantities in
lymphocyte numbers and cytokines but interestingly
consistent decrease in NK cytotoxic activity [15-20].
A decrease in NK cytotoxic activity is thus a recur-
ring finding in CFS/ME research [16,17,20-24] and
remains a hallmark of the disease. Additionally,
equivocal changes in NK cell subsets, CD56dimCD16+
and CD56brightCD16- NK cells have been shown to
occur [20,25]. Abnormalities in cellular levels of either
CD56dimCD16+ NK or CD56brightCD16- NK cells can
affect cytokine production and subsequent clearance
of pathogens. Despite these striking alterations there
are no follow up studies reporting on the profiling of
both NK cells subsets and activity during an extended
course of CFS/ME. Perturbations in cytokine produc-
tion favouring either an anti-inflammatory or pro-
inflammatory cytokine profile may be prevalent in
some CFS/ME patients [26-28]. CFS/ME is a chronic
disease with a relatively long duration, persisting for
more than 6 months, however, it is not reported yet
whether alterations in cytokines occur and persist over
time in adults with CFS/ME.
At this stage the diagnosis of CFS/ME is based on self-
reported clinical symptoms. The difficulty in establishing
a stringent medical diagnosis for CFS/ME may be related
to the lack of data monitoring the stability of immune
markers during the course of the disease. Almost all
studies to date investigating immune function in CFS/
ME including cell activity, lymphocyte subsets and cyto-
kines in CFS/ME adults were only restricted to singletime point examination, providing insufficient informa-
tion on the changes in these makers as the disease pro-
gresses. Additionally, there are many factors that can
affect the differences in data reported. As CFS/ME is
heterogeneous and multi-factorial, CFS/ME patients may
experience periods of high, medium or low severity in
symptoms which may be related to the levels of cyto-
kines and immune function.
Therefore, the purpose of this study is to examine the
validity and stability of immune parameters previously
known to be compromised in CFS/ME and to determine
most importantly whether these observations are con-
sistent during the course of the disease. Assessment and
evaluation of these markers potentially enables both the
determination and knowledge of their stability over the
course of the disease. This is the first longitudinal study
assessing NK cytotoxic activity, NK subsets and CD4+T
cell cytokine distribution over a period of 12 months in
adults suffering from CFS/ME.
Methods
Recruitment
Participants for this study were comprised of CFS/ME
patients and non-fatigued controls recruited from an
existing cohort in Queensland and New South Wales,
Australia [25]. Prior to inclusion all participants
completed a consent form and a questionnaire. The
description of these participants is provided in Table 1.
The CFS/ME group met the 1994 CDC criteria for
CFS/ME and the control group consisted of non-
fatigued volunteers. The non-fatigued controls were
recruited from similar locations as the CFS/ME cohort.
In both groups, individuals with known autoimmune
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related disorders prior to the onset of CFS/ME like
symptoms were excluded from the study. These exclu-
sions were also applied to the control group.
Data collection
Samples were collected at baseline (T1), after 6 months
(T2) and after 12 months (T3). Blood collections were
performed at three testing sites as it was not always fea-
sible for participants to travel to the main testing site.
Participants were recruited in 2009 and enlisted for the
study in December 2009. The first collection was per-
formed in December 2009. The second sampling point
took place in June 2010 and the third in December
2010. Clinical data were collected through self-
administered questionnaires at (T1) and T3.
Sample preparation and routine measurements
Non-fasting morning blood samples were collected from
the antecubital vein of all participants into lithium hep-
arin (12 mL) and EDTA (25 mL) tubes. Regular full
blood count (Coulter Counter, Beckman Coulter) assess-
ments were performed ahead of immunological assess-
ments. All analyses and experiments were performed
immediately following blood collection. On a given day
blood samples were collected from a maximum of 10
participants. These participants comprised of a mixture
of CFS/ME patients and non-fatigued controls, however,
as there were more CFS/ME patients compared to non-
fatigued controls, in some cases the samples comprised
only CFS/ME patients.
NK cytotoxic activity
NK cytotoxic activity was examined as previously
described [20,25,29]. In brief, NK lymphocytes were iso-
lated from blood samples using density gradient centri-
fugation and labelled with 0.4% PKH-26 (Sigma, St
Louis, MO). Following which NK cells were incubated
with K562 cells, for 4 hours at 37°C in 95% air, 5% CO2
at an effector to target ratio of 25 (NK cells):1 (K562).
An E:T ratio of 25:1 was chosen as we have previously
found this ratio to be the most optimal condition for
assessing cytotoxic activity. In previous studies this ratio
has been used [20,25]. After four hours of incubation
NK lysis of K562 cells was calculated as previously
described [29] to determine the ability of NK cells to in-
duce tumor cell death or apoptosis via FACS-Calibur
flow cytometry (BD Bioscience, San Jose, CA), using
Annexin V-FITC and 7-AAD reagents (BD Pharmingen,
San Diego, CA). The NK assay was performed within
2–4 hours upon receipt of all blood samples for that
particular day hence each sample was treated the same.
Each sample was performed in duplicates and a control
sample was included in each run.NK subsets
The frequency of NK cell subsets was evaluated as pre-
viously described [20,25]. Briefly, a negative selection
system using RosetteSep Human Natural Killer Cell
Enrichment Cocktail (StemCell Technologies, Vancouver,
BC) was used to segregate NK lymphocytes from whole
blood. Preferentially isolated NK cells were then labelled
with CD56-FITC and CD16-PE monoclonal antibodies
(BD Pharmingen, San Jose, CA). In a forward scatter
and side scatter plot created using the FACS-Calibur
flow cytometry, a lymphocyte gate was set on NK cells.
Subset profile was measured in a PE versus FITC plot.
T cell specific cytokine distribution
Isolated PBMCs were cultured at 1×106 cells/mL with or
without 1 μg of phytohemagluttinin for 72 hours. Cellular
supernatants were collected following incubation and
stored at −80°C for later assessment. Th1, Th2 and Th17
cytokine concentrations were determined using the
cytometric bead array (CBA) kit (BD Pharmingen, San
Jose, CA) [25,30]. The cytokines that were measured in-
clude IL-2, IL-4, IL-6, IL-10, tumour necrosis factor
(TNF)-α, interferon (INF)-γ and IL-17A. The CBA kit
includes a standard that is diluted at different concen-
trations as per manufacturer’s instructions to produce a
standard curve for each cytokine to be measured. This
was included in the cytokine assessment. During each
run of the CBA analysis control samples were included
and each set of samples analysed on a given day consisted
of both CFS/ME patients and non-fatigued control cell
supernatants.
Statistical analysis
Statistical analysis was performed using SPSS software
version 18.0. The experimental data represented in this
study are reported as means plus/minus standard error
of the mean (±SEM) while all the clinical date are
reported as means plus/minus standard deviation (±SD).
Comparative assessments among participants (CFS/ME
and non-fatigued controls) were performed with the
analysis of variance test (ANOVA) and repeated mea-
sures. For the repeated measures assessment time was
the within-subjects factor and group was the between
subject factor. Instances where Mauchly’s test indicated
that the sphericity assumption was breached, the
Huynh-Feldt correction was applied. The Bonferroni
method was used as post-hoc analysis to assess changes
in the data. Time effects and group effects on the vari-
ables measured were assessed using eta squared (η2),
where η2 is the ratio of the sum of squares of the
variance to the sum of squares of the total variance
(η2 = SSvariance effect/SStotal). To determine within
subject stability Pearson and Spearman’s rank correla-
tions were determined between the three time points.
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Ethical clearance and participant selection
Approval for this study was granted after review by the
Bond University Human Research Ethics Committee
(R0852A).
Results
Participants
Data for baseline, 6 months and 12 months were
available for 86 participants (65 CFS/ME patients andFigure 1 NK Cytotoxic activity was decreased at all time points in the
cells by NK cells assessed overtime at T1, T2 and T3 in the CFS/ME patients
showing the overall cytotoxic activity in the whole participant group. *Indi
presented as mean ± SEM.21 non-fatigued controls). The mean age for the CFS/
ME patients was 47.2 ± 11.5 years and 45.2 ± 9.3 years
for the non-fatigued controls. 75.4% of CFS/ME patients
and 66.7% of the non-fatigued controls were female
and the mean BMI in both groups was 24.5 ± 5.0 for
the CFS/ME patients and 24.5 ± 4.3 for the non-
fatigued controls. The CFS/ME patients had been suf-
fering from fatigue for a mean of 16.4 ± 12.5 years and
their mean score on the Fatigue Severity Scale (FSS)
was 55.5 ± 9.1 (the lowest possible score of the FSS was
7 and highest is 63) [31]. Only 19.4% of patients indi-
cated that they were still able to carry out normalCFS/ME patients. (A) Cytotoxic activity presented as % lysis of K562
(black bars) and control (white bars) participants. (B) Cluster analysis
cates statistical significant results relative to controls. Statistics are
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in Table 1.
Longitudinal assessment of NK cytotoxic activity
NK cytotoxic activity, that is, the ability of the NK cells to
effectively cause apoptosis of K562 cells was significantlyFigure 2 CD56brightCD16-NK Subset was decreased in the CFS/ME gro
significantly low in the CFS/ME group at the T1 and at T2. The white bars r
Cluster analysis showing the overall cytotoxic activity in the whole particip
collected via flow cytometery ± SEM. *Signifies statistical significant resultsreduced (p< 0.05) in CFS/ME patients compared to
the control group. Significant changes between the
groups were noticed at the different time points, i.e.
at T1 (p< 0.001), T2 (p< 0.001) and T3 (p< 0.001)
(Figure 1A). Regardless of the time point cytotoxic activity
remained significantly decreased (p< 0.001). Time effectsup. Percentage of NK cells stained positive for CD56brightCD16- was
epresent control data while the black bars represent CFS/ME data. (B)
ant group. Data are presented in the form of log of the total events
relative to controls.
Figure 3 (See legend on next page.)
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Figure 3 Between group differences in cytokine production overtime. The secretion of IL-2 (A) was significantly increased in the CFS/ME
patients at the T3, (B) IL-10 increased at the T1 and dropped significantly at the T2 in the CFS/ME group. (C) IL-17A was reduced at the T1 while
(D) IFN-γ and (E) TNF-α were increased significantly only at the T1. The CFS/ME data are signified by the black bars and non-fatigued controls the
white bars. *Symbolizes statistically significant results were considered where p≤ 0.05. The results are expressed as the mean concentration at
each time point ± SEM.
Brenu et al. Journal of Translational Medicine 2012, 10:88 Page 7 of 11
http://www.translational-medicine.com/content/10/1/88had no interaction with the group (p = 0.495). There
were significant time effects cytotoxic activity from
T1 to T3 (p = 0.023) and from T2 to T3 (p = 0.016)
(Figure 1B).
Differential distribution of NK cells between groups
NK subsets were classified as CD56dimCD16+ and
CD56brightCD16- NK cells. CD56brightCD16- NK cells
were significantly lower at T1 (p= 0.020) and T2
(p< 0.001) in CFS/ME patients compared to non-
fatigued controls (Figure 2A). Significant time effects
were observed for CD56brightCD16-NK cell (p= 0.003)
in the overall group. Additionally, there was a signifi-
cant interaction between time and group (p = 0.015).
Pairwise comparison revealed significant changes in the
overall group from the T1 to T2 (p = 0.037) and from T1
to T3 (p = 0.014) (Figure 2B). CD56dimCD16+NK cells
remained unchanged throughout the study for both
groups.
T cell related cytokine distribution
Mitogenic stimulation produced significant differences
in cytokine distribution observed at T1, T2 and T3. At
T1, IL-10 (p= 0.051), IFN-γ (p= 0.003) and TNF-α
(p=0.002) were significantly increased in the CFS/ME
patients compared to the non-fatigued controls
(Figure 3B, D, E). IL-10 (p=0.026) and IL-17A (p= 0.002)
were significantly decreased at T2 (Figure 3B, C) and only
IL-2 (p=0.005) was significantly increased at T3
(Figure 3A). There was no significant difference in the
remaining cytokines.
The production of some cytokines was significantly
different from one time point to another. IL-2 was
increased from T1 to T2 (p< 0.001) and from T1 to T3
(p< 0.001) (Figure 4A). IL-17A was increased from T1
to T2 (p= 0.009) but declined from T2 to T3 (p = 0.022)
(Figure 4D). Secretion of IL-6 was decreased from T1
to T2 (p= 0.001) and T1 to T3 (p= 0.001) (Figure 4B).
IL-10 progressively declined from T1 to T3 (p< 0.001)
and T2 to T3 (p <0.001) (Figure 4C).
Parameter stability
In this study the stability of the immune parameters over
time was assessed using Pearson and Spearman’s correl-
ation analysis, where significance was set at P less than
or equal to 0.05. The results were highly significant for
NK activity data (T1-T2; p= 0.003, T1-T3; p= 0.032).Although, CD56brightCD16-NK cells were not signifi-
cantly decreased at T3 the correlation between time
points was significant (T1-T2; p< 0.0001, T1-T3;
p< 0.0001, T2-T3; p< 0.0001). Of note, cytokines were
not correlated at any time point. However decreases in
IFN-γ, TNF-α and IL-10 were correlated at T1.
Discussion
Our investigation is the first study to demonstrate that
NK cytotoxic activity remains consistently decreased in
CFS/ME patients during the course of the disease. How-
ever, other immune parameters, especially cytokine
secretions fluctuate at different time points and there-
fore demonstrate inconsistencies in their distribution
pattern during the course of the disease. The purpose of
this investigation was to identify immune markers that
can be possibly used as biomarkers for CFS/ME in a lon-
gitudinal manner.
Primarily, this longitudinal study has illustrated that
NK cytotoxic activity is potentially useful as a biomarker
for CFS/ME, since it was the most stable in the CFS/ME
patients over the 12 months period of the study.
Decreases in cytotoxic activity occur in CFS/ME and in
some cases this is associated with differential expression
in the levels of cytotoxic molecules [20,21,32,33]. These
cytotoxic proteins and their genes including perforin
(PRF1), granzyme A (GZMA), granzyme B (GZMB) and
granzyme K (GZMK) have been shown to be either
increased or decreased in CFS/ME [24,25,34]. For ex-
ample, the perforin gene (PRF1) may increase in some
cases of CFS/ME while intracellular perforin protein
may be decreased in other CFS/ME patients [25]. Such
profound differences in protein and mRNA can reduce
the effectiveness of NK cells to induce lysis/cytotoxic ac-
tivity of viral infected cells. Hence, defective cytotoxic
activity in CFS/ME patients may be due to perturbations
in the expression of cytotoxic factors resulting in reduc-
tions in cytotoxic proteins required for effective lysis of
viral and microbial particles. Importantly, NK cells have
both activating and inhibitory receptors, successful kill-
ing of target cells occurs through integrated signalling
by activating and inhibitory receptors, and co-receptors.
Inhibitory receptors are activated through the recogni-
tion of MHC class I proteins and this inhibits NK
cytoxic activity [35,36]. Activating receptors are impor-
tant for eliminating tumours, and other microbes
through intracellular signal transduction mechanisms
Figure 4 Overall Cytokine Secretion with respect to time. (A) Cytokine production within group was significantly different in IL-2 with high
levels noticed at T1 compared to the T2 and T3 months. (B) A similar pattern was noticed in IL-2. (C) IL-10 was however significantly decreased
at T3 compared to the T1 or at T2. (D) IL-17A tended to be higher at T2 within group. Data are presented in the form of log of the total events
collected via flow cytometery ± SEM. *Designates statistical significant results relative to controls.
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activation motif (ITAMS) adaptor proteins [35-37]. Cer-
tain viruses can affect NK receptor signalling thus redu-
cing cytoxic activity. For example, the cytomegalovirus
viral genes can regulate NK inhibitory receptor expres-
sion preventing the induction of activating receptors
[38]. An increase in viral load occuring during the course
of CFS/ME, may trigger defective cytotoxic receptor
activations hence resulting in compromises to NK cytotoxic
activity. The significance of the overall decrease in cytotoxic
activity at T3 is unclear.
The exact consequence of alterations in CD56brightCD16-
NK cells in CFS/ME is not fully known, however,
patterns of CD56brightCD16- NK cells were affected by
seasonal changes which may affect NK cytokine produc-
tion. Incidentally gene expression of IFNG which is an
important NK cytokine was significantly decreased in the
NK cells of CFS/ME patients [25], which may be related
to the decrease in CD56brightCD16- NK cells. Decreases
in CD56brightCD16- NK cells have been observed in cor-
onary heart disease, allergic rhinitis and juvenile rheuma-
toid arthritis while in diseases such as Chronic
Obstructive Pulmonary Disease (COPD) CD56brightCD16-
NK cells have been reported to be increased [39,40].
IL-2, a pro-inflammatory cytokine produced by Th1
cells [41] is required for naïve CD4+T cell differentiation
into Th2 and regulatory T cells (Tregs) in the presence
of IL-4 and transforming growth factor beta (TGF-β)
respectively [41]. Binding of IL-2 to its high affinity
receptor IL-2R induces the proliferation of T cells and
memory CD4+ and CD8+T cells [42-44]. It is also has
important roles in generating effector functions for B
cells, CD56brightNK and CD8+T cells [45]. IL-2 regulates
Treg cells and interestingly, CD4+CD25+Foxp3+Treg
cells, have been reported to be significantly increased in
the CFS/ME patients in comparison to non-fatigued
controls [25]. An increase in IL-2 may suggest a shift
towards Th1/pro-inflammatory immune response in
CFS/ME patients.
Anti-inflammatory IL-10 exerts inhibitory effects on
cytokine secretion and impedes pro-inflammatory cyto-
kine secretion by multiple cells including Th1 cells
(IFN-γ), macrophages/monocytes (IL-1, IL-T2, IL-8,
IL-12 and TNF-) and NK cells (IFN-γ and TNF-α) [46].
A decrease in IL-10 favours an increase in pro-
inflammatory responses and this may increase the
prevalence of Th1 like cytokines. IL-17A is expressed by
Th17 cells, it recruits and activates neutrophils, stimu-
lates the generation of pro-inflammatory cytokines, che-
mokines and increases antimicrobial gene expression
[47-50]. IL-17A is therefore an important immunoregu-
lator during microbial infections as it activates immune
cells to secrete pro-inflammatory factors. A decrease in
IL-17A may contribute to the prevalence of infections.A possible explanation for the observed changes in the
secretion of this cytokine may be related to TGF-β
which at optimal levels directly promotes IL-17A gener-
ation while reducing IL-2 [51]. Thus, in the CFS/ME
patients, TGF-β may be decreased causing an increase
in IL-2. Therefore, cytokine release in CFS/ME patients
undergoes shifts during the course of the disease where
patients may present with either an amplified or
depressed anti-inflammatory or pro-inflammatory cyto-
kine profile. These alterations in cytokine secretion may
occur during the course of the disease and at different
times causing either a shift towards a predominant Th1
or Th2 immune response in CFS/ME [25-27,52,53]. This
makes it difficult to establish a unique CFS/ME-like in-
flammatory cytokine profile. The observed pattern of
cytokine distribution among our CFS/ME patients is con-
sistent with equivocal findings in the literature [54-58].
In adolescents with CFS/ME cytokine secretions have
been observed to be correlated with seasonal variations
[59]. Therefore, CFS/ME may be associated with oscilla-
tions in pro and anti-inflammatory cytokines, supporting
the heterogeneity and multifactorial nature of the disease
and the diversity in symptom presentations.
Conclusion
In conclusion, altered regulation of immunological func-
tion, in particular reduced cytotoxic activity of innate
immune cells, is a key component of CFS/ME. This lon-
gitudinal study has identified NK cytotoxic activity and
possibly CD56brightCD16- NK cells as potential biomar-
kers for diagnosing CFS/ME. The observation of im-
mune dysregulation made in this study in relation to
CFS/ME patients have been observed in various im-
munological diseases. This suggests the need for further
investigations into the underlining disrupted mechanism
of decreases in cytotoxic activity. It is important to note
that these cytokine profiles were measured following
mitogenic stimulation of PMBCs, serum measurements
of cytokines may display different results. Further studies
are therefore required to investigate whether changes in
cytokine secretions from activated PMBCs and/or serum
levels are associated with severity and progression of the
complex clinical presentations in CFS/ME pathology.
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